Please ensure Javascript is enabled for purposes of website accessibility

Why Spectrum Pharmaceuticals, Inc. Is Soaring Today

By Brian Feroldi - Apr 10, 2018 at 11:07AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Traders cheer after the company shares additional data from an important phase 2 trial.

What happened

After releasing updated data from a phase 2 study, shares of Spectrum Pharmaceuticals (SPPI 4.57%), a red-hot biotech focused on hematology and oncology, rose 21% as of 10:30 a.m. EDT on Tuesday.

So what

Spectrum announced updated data from a phase 2 trial that is studying a compound called poziotinib as a hopeful treatment for non-small cell lung cancer.

Here's an overview of the key announcements made today:

  • The confirmed objective response rate from the 11 patient trial was 64%. That's much higher than the 20% to 30% response rate that the study investigators were hoping for.
  • The median progression-free survival rate has still not been reached even after a median follow up period of 6.5 months.
  • Enrollment is exceeding expectations.
  • The two most common adverse events that were observed in the study are skin rash and diarrhea.

Here's what Spectrum's CEO Joe Turgeon had to say about this data release:

The updated data from MD Anderson provides additional insight into just how meaningful poziotinib may be in this area of high unmet need. At each turn, the possibility of this drug as an option for EGFR Exon 20 mutant NSCLC patients is becoming more clear.

Given the news, it isn't hard to figure out why Wall Street is bidding up the share price today.

Businessman giving thumbs up as smiling doctor sits nearby.

Image source: Getty Images.

Now what

Today's update should provide investors with some confidence that poziotinib is going to be a winner, but it is also important to remember that this is just data from an 11 patient phase 2 trial. It is unknown whether or not the company will be able to repeat these positive results in a much larger trial.

The company stated that it will share a more thorough review of this data at a major medical meeting later this year. Bulls and bears alike will want to tune in for clues as to what the future may hold for this potentially lucrative compound.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Spectrum Pharmaceuticals, Inc. Stock Quote
Spectrum Pharmaceuticals, Inc.
$0.74 (4.57%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.